Non-invasive monitoring of photodynamic therapy with 99technetium HMPAO scintigraphy.
The effect of photodynamic therapy (PDT) on tumour perfusion in both anaplastic (R3327-AT) and well differentiated (R3327-H) Dunning prostatic tumours was studied using the radiopharmaceutical 99Technetium hexamethylpropyleneamine oxime (99mTc-HMPAO). Tumours in the left flanks of rats (Copenhage x Fischer, F1 hybrids) were treated with interstitial PDT when their volumes reached 2-3 cm3. Qualitative and quantitative data from pre- and post-PDT scintigraphy revealed a light-dose-dependent shut-down of tumour perfusion which was also time-dependent. Maximal shut-down, following a 1,600 J light-dose, occurred about 8 h post-PDT. Light exposure 2 h after the intravenous administration of the photosensitiser (Photofrin II) produced a greater vascular shut-down than did light exposure 24 h after the administration of the drug. Regional differences in perfusion within treated and non-treated tumours were measured by tomographic procedures. Light-dose-dependent volumes of perfusion shut-down were demonstrated in addition to the naturally occurring regional differences in tumour perfusion. This radiopharmaceutical may have future utility for monitoring the clinical treatment of solid tumours with PDT.
Moore
R B
RB
Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Chapman
J D
JD
Mokrzanowski
A D
AD
Arnfield
M R
MR
McPhee
M S
MS
McEwan
A J
AJ
D000818:Animals; D002454:Cell Differentiation; D008297:Male; D009374:Neoplasms, Experimental; D015609:Organotechnetium Compounds; D010091:Oximes; D010778:Photochemotherapy; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000628:therapy*; D011877:Radionuclide Imaging; D051381:Rats; D019690:Technetium Tc 99m Exametazime
D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime